| Authors: |
Camidge DR; University of Colorado Cancer Center, Aurora, Colorado., Barlesi F; Assistance Publique Hôpitaux de Marseille, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale Centre National de la Recherche Scientifique, Aix Marseille University, Marseille, France.; Gustave Roussy, Villejuif, France., Goldman JW; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California., Morgensztern D; Washington University School of Medicine, St. Louis, Missouri., Heist R; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Vokes E; University of Chicago Medicine, Chicago, Illinois., Angevin E; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France., Hong DS; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rybkin II; Henry Ford Health System, Detroit, Michigan., Barve M; Mary Crowley Cancer Research Center, Dallas, Texas., Bauer TM; Sarah Cannon Research Institute, Nashville, Tennessee., Delmonte A; Medical Oncology Division, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Dunbar M; AbbVie Inc., North Chicago, Illinois., Motwani M; AbbVie Inc., North Chicago, Illinois., Parikh A; AbbVie Inc., Redwood City, California., Noon E; AbbVie Inc., North Chicago, Illinois., Wu J; AbbVie Inc., North Chicago, Illinois., Blot V; AbbVie Inc., Redwood City, California., Kelly K; University of California Davis Comprehensive Cancer Center, Sacramento, California. |
